Letters NICE on ovarian cancer

NICE’s reply

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d3519 (Published 07 June 2011) Cite this as: BMJ 2011;342:d3519
  1. Sean Duffy, medical director1
  1. 1Yorkshire Cancer Network, Harrogate HG2 7RY, UK
  1. sean.duffy{at}ycn.nhs.uk

The National Institute for Health and Clinical Excellence (NICE) guideline aims to reduce the number of women dying from ovarian cancer because of late diagnoses.1 2

Evidence shows that the CA125 blood test is the most reliable and widely used tumour marker available. Because the four key symptoms are non-specific, it would be costly and of little clinical benefit …

View Full Text

Log in

Log in through your institution


* For online subscription